Loading
A phase 2 trial of DNX-2401 run by DNAtrix, Inc., completed.
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects is a phase 2 interventional study registered as NCT02798406 by DNAtrix, Inc., with 49 participants enrolled, started 2016-10-06. Conditions recorded: Brain Cancer, Brain Neoplasm, Glioma, Glioblastoma, Gliosarcoma, Malignant Brain Tumor, Neoplasm, Neuroepithelial, Neuroectodermal Tumors, Neoplasm by Histologic Type, Neoplasm, Nerve Tissue and Nervous System Diseases. Interventions recorded: DNX-2401 and pembrolizumab.
Shares DNX-2401, DNAtrix, Brain and spinal cord tumours (all types), Glioma & glioblastoma and the tag pipeline.
Shares DNX-2401, DNAtrix, Glioma & glioblastoma, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares DNX-2401, DNAtrix, Brain and spinal cord tumours (all types) and the tag pipeline.
Shares DNX-2401, DNAtrix, Brain and spinal cord tumours (all types) and the tag pipeline.
Shares DNX-2401, DNAtrix, Glioma & glioblastoma and the tag pipeline.
Shares DNX-2401, DNAtrix, Brain and spinal cord tumours (all types) and the tag pipeline.
Shares DNX-2401, DNAtrix, Brain and spinal cord tumours (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/